Lymphoproliferative syndrome
MONDO:0016537A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).
Also known as: lymphoproliferative disorder, lymphoproliferative syndrome
138 clinical trials for this condition and its sub-types, 70 tagged with Lymphoproliferative syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lymphoproliferative syndrome
-
Castleman disease 8 trials · 18 incl. sub-types
4 sub-types
- Multicentric Castleman disease 13 trials
- Idiopathic multicentric Castleman disease 3 trials Sub-types →
- Localized Castleman disease 1 trial
- Pediatric Castleman disease 0 trials
-
Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types
9 sub-types
- Autoimmune lymphoproliferative syndrome type 4 3 trials
- FAS-related autoimmune lymphoproliferative syndrome 2 trials
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency 1 trial
- Castleman-Kojima disease 0 trials
- Autoimmune lymphoproliferative syndrome type 1 0 trials
- Autoimmune lymphoproliferative syndrome type 2A 0 trials
- Autoimmune lymphoproliferative syndrome type 2B 0 trials
- Autoimmune lymphoproliferative syndrome, type III caused by mutation in PRKCD 0 trials
- Type 3 autoimmune lymphoproliferative syndrome 0 trials
-
X-linked lymphoproliferative syndrome 7 trials · 11 incl. sub-types
2 sub-types
-
Lymphoproliferative syndrome 1 0 trials
-
Lymphoproliferative syndrome 2 0 trials
-
Experimental antibody GNR-084 tested against Hard-to-Treat leukemia
Disease control Stopped earlyResearchers are testing an experimental antibody called GNR-084 in adults with B-cell acute lymphoblastic leukemia that has come back or stopped responding to treatment. The trial enrolls 14 people aged 18 to 45 who have already received at least two prior therapies. Participants…
Phase 1/2 • Sponsor: AO GENERIUM • Aim: Disease control
Last updated Sep 21, 2026 13:00 UTC
-
New cocktail of cancer drugs tested in desperate cases
Disease control Stopped earlyThis early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC